GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guerbet SA (XPAR:GBT) » Definitions » YoY EBITDA Growth

Guerbet (XPAR:GBT) YoY EBITDA Growth : 32.05% (As of Dec. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Guerbet YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Guerbet's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 32.05%.

Guerbet's EBITDA per Share for the six months ended in Dec. 2023 was €5.32.


Guerbet YoY EBITDA Growth Historical Data

The historical data trend for Guerbet's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guerbet YoY EBITDA Growth Chart

Guerbet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.39 -25.85 6.99 7.23 3.27

Guerbet Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.82 -19.90 58.65 -19.54 32.05

Guerbet YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Guerbet's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(8.115-7.858)/ | 7.858 |
=3.27 %

Guerbet's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(5.319-4.028)/ | 4.028 |
=32.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guerbet YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Guerbet's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Guerbet (XPAR:GBT) Business Description

Traded in Other Exchanges
Address
15 rue des Vanesses, Zone Paris Nord II, Villepinte, FRA, 93420
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.

Guerbet (XPAR:GBT) Headlines